Oxford BioDynamics' EpiSwitchâ„¢ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

Author's Avatar
Nov 09, 2019
Article's Main Image

- Data from study of EpiSwitch™ suggest independent predictive power of the 3D genome architecture technology platform in immuno-oncology

- Posters presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting co-authored by scientists from Merck KGaA, Darmstadt, Germany, Pfizer and Mayo Clinic

PR Newswire